Trial
NCT05103904
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Emory University
Collaborators
National Cancer Institute (NCI); Eisai Co., Ltd.
Condition
Recurrent Hepatocellular Carcinoma
Intervention
Laboratory Biomarker Analysis
Why stopped
Slow Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-24